Featured
-
-
Article
| Open Access
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
Unveiling the regulation of mitotic protein degradation is crucial for cancer therapy. Here, the authors reveal that a reciprocal inhibition of PIN1-APC/CCDH1 controls the cell cycle and mitotic protein degradation, offering a synergistic anti-tumor strategy.
- Shizhong Ke
- , Fabin Dang
- & Kun Ping Lu
-
Article
| Open Access
Tumor-activated in situ synthesis of single-atom catalysts for O2-independent photodynamic therapy based on water-splitting
The utility of single-atom catalysts (SACs) for photodynamic therapy (PDT) has been limited by tumor hypoxia and side effects on normal tissues. Here the authors address these issues by developing an approach of tumor microenvironment-activated in situ synthesis of SACs for tumor-specific water-based PDT.
- Yiyan Yin
- , Xiyang Ge
- & Na Na
-
Article
| Open Access
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
ATR/CHK1 pathway inhibitors represent a therapeutic option for platinum-resistant high-grade serous ovarian carcinoma (HGSOC). Here the authors report the results of a phase 2 clinical study of the CHK1 inhibitor prexasertib in patients with BRCA wild-type platinum-resistant HGSOC with or without biopsiable disease.
- Elena Giudice
- , Tzu-Ting Huang
- & Jung-Min Lee
-
Perspective
| Open Access
Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer
Hyperactivation of YAP/TAZ, the Hippo pathway downstream effectors, is common in human cancer. In this perspective, the authors review the role of the Hippo pathway in distinct tumor cell populations, discuss the impact of inhibiting Hippo output on tumor growth, and examine current developments in YAP/TAZ inhibitors.
- Isabel Baroja
- , Nikolaos C. Kyriakidis
- & Iván M. Moya
-
Article
| Open Access
Outcome differences by sex in oncology clinical trials
The role of sex differences in response to cancer therapy remains unclear but this could be improved by reporting sex comparisons of outcomes in clinical trials. Here, the authors characterise the sex outcome comparisons in 89,221 interventional trials, finding that while comparisons were rare, important insights could be obtained.
- Ashwin V. Kammula
- , Alejandro A. Schäffer
- & Eytan Ruppin
-
Article
| Open Access
Oxygen-independent organic photosensitizer with ultralow-power NIR photoexcitation for tumor-specific photodynamic therapy
Conventional photodynamic therapy (PDT) is hindered by oxygen-dependent photosensitization pathways and high-power-density photoexcitation. Here, the authors develop polymer-based organic photosensitizers (PSs) through PS skeleton design and side-chain engineering to allow tumor-specific PDT under oxygen-free conditions using ultralow-power 808 nm photoexcitation.
- Yufu Tang
- , Yuanyuan Li
- & Bin Liu
-
Article
| Open Access
Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability
MYC oncogene promotes tumourigenesis by coordinating cancer cell proliferation with metabolic adaptation to the consequent excessive oxidative stress. Here, the authors show that nudix hydrolase 1 (NUDT1) is a MYC-driven metabolic vulnerability and generate a NUDT1 protein degrader to treat preclinical MYC-associated cancer.
- Minhui Ye
- , Yingzhe Fang
- & Guoliang Qing
-
Article
| Open Access
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
CDK4/6 inhibitors have improved outcomes for patients with ER+ breast cancer, however, those with loss of RB1 function often fail to respond. Here, the authors identify a vulnerability of ER + /RB1- breast cancer on PRMT5 and via dual blockade of ER and PRMT5 therapeutically target this in patient-derived xenograft models.
- Chang-Ching Lin
- , Tsung-Cheng Chang
- & Carlos L. Arteaga
-
Article
| Open Access
Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models
Therapeutic options for pancreatic ductal adenocarcinoma (PDAC) are limited. Here the authors report the characterization of a CEACAM6-targeting antibody drug conjugate loaded with a BET protein degrader, showing antitumour activity in PDAC preclinical models.
- Youya Nakazawa
- , Masayuki Miyano
- & Akihito Machinaga
-
Article
| Open Access
Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation
The benefit of hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer remains controversial. Here, the authors perform a multi-omics analysis of hyperthermia-treated ovarian cancer cells, show that CDK1 becomes hyperactivated and regulates signalling upon hyperthermia, and identify WEE1 as a synergistic therapeutic target for hyperthermic intraperitoneal therapy.
- Xiaohang Yang
- , Xingyuan Hu
- & Chaoyang Sun
-
Article
| Open Access
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma
The application of fibroblast growth factor receptor (FGFR)−2 selective tyrosine kinase inhibitors (TKIs) in cholangiocarcinoma (CCA) with FGFR2 fusions has been reported to lead to mutations in the kinase domain of FGFR2.
Here, the authors report that non-selective TKI, lenvatinib may be an alternative in case of insurmountable side effects to specific FGFR inhibitors or to overcome and delay the development of resistance mediating FGFR2 mutations.
- Stephan Spahn
- , Fabian Kleinhenz
- & Michael Bitzer
-
Article
| Open Access
Regulating protein corona on nanovesicles by glycosylated polyhydroxy polymer modification for efficient drug delivery
The dynamic protein corona hinders the uptake of nanocarriers in desired target cell populations, limiting their bench-to-bedside translation. Here the authors reveal that the modification of hydroxyl and amino functional groups on nanovesicles can rationally regulate the composition of protein coronas to improve the efficiency of targeted drug delivery.
- Yunqiu Miao
- , Lijun Li
- & Yong Gan
-
Article
| Open Access
Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer
Resistance to cetuximab is a common feature of colorectal cancer progression. Here, the authors utilize longitudinal proteomic profiling of 147 colorectal cancer patients and find potential biomarkers which can predict treatment response.
- Yan Li
- , Bing Wang
- & Chen Ding
-
Article
| Open Access
In-situ-sprayed therapeutic hydrogel for oxygen-actuated Janus regulation of postsurgical tumor recurrence/metastasis and wound healing
Surgery is a primary therapeutic modality for treating melanoma, but it is challenging to tackle tumor recurrence/metastasis and postsurgical wounds. Here the authors report a sprayable hydrogel capable of long-lasting and controllable oxygen supply for preventing tumor recurrence/metastasis and simultaneously promoting wound healing during the postsurgical treatment of melanoma.
- Shuiling Chen
- , Yang Luo
- & Shaobing Zhou
-
Article
| Open Access
In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy
The poor tumour delivery efficacy of GPX4 inhibitor has dampened its in vivo therapeutic value. Here the authors report a peptide ferriporphyrin conjugate to improve tumour penetration, endocytosis and GPX4 inhibition, synergistically enhancing its anticancer activity by ferroptosis.
- Da-Yong Hou
- , Dong-Bing Cheng
- & Hao Wang
-
Article
| Open Access
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
HER2 targeted therapy combined with chemotherapy represents a standard approach for treating HER2-positive metastatic breast cancer (MBC). Here the authors report the results of a phase II trial of the small molecule tyrosine kinase inhibitor pyrotinib plus docetaxel as a first-line treatment for HER2-positive MBC.
- Yabing Zheng
- , Wen-Ming Cao
- & Xiaojia Wang
-
Article
| Open Access
Mirabegron displays anticancer effects by globally browning adipose tissues
Targeting metabolism is currently a promising approach for cancer treatment. Here, the authors show that the beta3 agonist mirabegron inhibits tumor progression by browning adipose tissues in preclinical murine models.
- Xiaoting Sun
- , Wenhai Sui
- & Yihai Cao
-
Article
| Open Access
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
Here, the authors identify lysine-specific demethylase 1 is a homologous recombination (HR) regulator. Its inhibitor induces HR deficiency and sensitizes HR-proficient ovarian cancer cells to PARP inhibitors, which expand the use of PARP inhibitors.
- Lei Tao
- , Yue Zhou
- & Yinglan Zhao
-
Article
| Open Access
A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics
Combining chemotherapeutics can be beneficial but identifying effective combinations from the vast array of possibilities is resource and time consuming. Here, the authors perform a high-throughput targeted CRISPR knock-out screen identify druggable gene targets which alter sensitivity to chemotherapies. In doing so, they identify DNA-PK inhibition as a sensitiser of neuroblastomas to doxorubicin.
- Hyeong-Min Lee
- , William C. Wright
- & Paul Geeleher
-
Article
| Open Access
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer
Resistance to standard of care (SOC) therapies reduces survival of estrogen receptor-positive (ER+) breast cancer patients. Here the authors show that SOC therapy downregulates the ER target phosphodiesterase 4D (PDE4D), causing DNA damage and cell death upon generation of functional BRCAness, and that combining SOC with inhibitors of PDE4D, EGFR or PARP1 overcomes SOC resistance irrespective of the BRCA1/2 status.
- Ozge Saatci
- , Metin Cetin
- & Ozgur Sahin
-
Article
| Open Access
An autocatalytic multicomponent DNAzyme nanomachine for tumor-specific photothermal therapy sensitization in pancreatic cancer
Despite delivering gene-specific silencing, the use of deoxyribozymes (DNAzymes) for cancer therapy is limited by toxicity due to off-target effects. Here, the authors develop a multi-component DNAzyme, targeting both miRNA21 and HSP70, to induce tumour-specific sensitisation to photothermal therapy in preclinical models of pancreatic cancer.
- Jiaqi Yan
- , Xiaodong Ma
- & Hongbo Zhang
-
Article
| Open Access
NIR-dye bridged human serum albumin reassemblies for effective photothermal therapy of tumor
Human serum albumin (HSA) can be used as a drug delivery material for cancer therapy. Here, the authors report an HSA-based photothermal platform that improves drug loading and photothermal therapeutic performance in breast cancer mouse models.
- Zhaoqing Shi
- , Miaomiao Luo
- & Hongzhong Chen
-
Article
| Open Access
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
The success of targeting KRAS for cancer therapy is limited by resistance due to compensatory mechanism, making combinatorial approaches attractive. Here, the authors use a KRAS signature drug repurposing screen and identify the multityrosine kinase PKC inhibitor Midostaurin as synergistic with MEK and KRAS inhibitors in KRAS-mutated lung adenocarcinoma.
- Irati Macaya
- , Marta Roman
- & Silve Vicent
-
Article
| Open Access
URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers
Despite being a promising treatment for hepatocellular carcinoma (HCC), resistance to tyrosine kinase inhibitors (TKI) present a major obstacle. Here, the authors demonstrate that lipid metabolism reprogramming via URI mediated stearoyl-CoA desaturase 1 upregulation present a targetable driver of sorafenib resistance in HCC.
- Zhiwen Ding
- , Yufei Pan
- & Lu Wang
-
Article
| Open Access
Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours
Chimeric antigen receptor T (CAR-T) cells represent an emerging form of immune therapy but success, especially in solid tumors, is limited by the scarcity of suitable target epitopes. Here authors show that a distinct epitope motif on the transmembrane protein B7-H3, recognized by a camel nanobody, triggers robust activation and anti-tumor function in cognate CAR-T cells.
- Dan Li
- , Ruixue Wang
- & Mitchell Ho
-
Article
| Open Access
Pre-activated nanoparticles with persistent luminescence for deep tumor photodynamic therapy in gallbladder cancer
Phototherapy of deep tumors suffers from many obstacles, such as limited near-infrared tissue penetration depth and low accumulation efficiency within the target sites. Here, the authors report stimuli sensitive tumor-targeted photodynamic nanoparticles with persistent luminescence for the treatment of deep tumors.
- Sarun Juengpanich
- , Shijie Li
- & Mingyu Chen
-
Article
| Open Access
KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics
The molecular mechanisms involved in the maintenance of pancreatic cancer stem cells (PCSCs) characteristics are unclear. Here, the authors identify the histone methyltransferase KMT2A as a binding partner of the PHF5A-PHF14-HMG20A-RAI1 protein subcomplex and an epigenetic regulator of the PCSCs characteristics and show the therapeutic potential of targeting this axis in pancreatic cancer.
- Mai Abdel Mouti
- , Siwei Deng
- & Siim Pauklin
-
Article
| Open Access
Nanocompartment-confined polymerization in living systems
Polymerizations in living systems can effectively regulate cell functions and behaviors, but their uses have been hindered by the existence of complicated intracorporal interferences, the needs of high concentration of monomers and extra stimulates. Here, the authors address these issues by developing a nanocompartment-confined strategy to achieve broad-spectrum polymerizations in living systems.
- Yun Chen
- , Mengxuan Zuo
- & Yanli Zhao
-
Article
| Open Access
TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation
Proliferation of cancer cells leads to replication stress through incompletely understood mechanisms. Here, the authors show that the long noncoding RNA TUG1 resolves R-loops and reduces replication stress in cancer cells.
- Miho M. Suzuki
- , Kenta Iijima
- & Yutaka Kondo
-
Article
| Open Access
Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
HER2-low breast cancer has recently been defined as a potential subtype for sensitivity to novel antibody-drug conjugates. Here, the authors analyse a multiomics cohort of 434 HER2-low patients and find an altered molecular status compared to other subtypes and the interpatient heterogeneity within this subtype.
- Lei-Jie Dai
- , Ding Ma
- & Zhi-Ming Shao
-
Article
| Open Access
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Patients with estrogen receptor positive breast cancer (ER + BC) treated with palbociclib (CDK4/6 inhibitor) frequently develop resistance. Here, the authors identify a reliance of palbociclib resistance on oxidative phosphorylation (OXPHOS) and therapeutically target this vulnerability using an OXPHOS inhibitor, restoring sensitivity in ER + BC preclinical models.
- Rania El-Botty
- , Ludivine Morriset
- & Elisabetta Marangoni
-
Article
| Open Access
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
Patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions are resistant to early generation EGFR tyrosine kinase inhibitors (TKI). Here, the authors report the safety and preliminary efficacy of a phase I clinical trial JMT101, an anti-EGFR antibody, combined with EGFR-TKI, afatinib or osimertinib, in patients with NSCLC.
- Shen Zhao
- , Wu Zhuang
- & Wenfeng Fang
-
Article
| Open Access
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
HER2 amplification in metastatic colorectal cancer (mCRC) identifies a group of patients with poorer prognosis. Here, the authors report the results of a phase II clinical trial assessing the clinical response and safety of trastuzumab deruxtecan as a third-line treatment in patients with mCRC with different HER2 expression levels
- Takayuki Yoshino
- , Maria Di Bartolomeo
- & Maria Di Bartolomeo
-
Article
| Open Access
Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase
Novel strategies are needed to overcome chemotherapy resistance. Here the authors report chemotherapy induces the phosphorylation of Lysyl oxidase-like 3, which in turn stabilizes dihydroorotate dehydrogenase (DHODH) and that DHODH inhibitor sensitizes tumor cells to oxaliplatin treatment by inducing ferroptosis in liver cancer.
- Meixiao Zhan
- , Yufeng Ding
- & Xiongjun Wang
-
Article
| Open Access
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance
The molecular mechanisms involved in the development of SMARCB1-deficient renal medullary carcinomas (RMCs) remain to be characterised. Here, the authors integrated RMC omics data to show that ferroptosis resistance contributes to transformation of renal thick ascending limb cells into several RMC cell states.
- Bujamin H. Vokshi
- , Guillaume Davidson
- & Gabriel G. Malouf
-
Article
| Open Access
Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss
Cancers with concomitant SMARCA4/2 deficiencies are often resistant to chemotherapies and confer a poor prognosis. Here, the authors identify a metabolic dependency of these tumours on glutamine as an energy source and, using multiple approaches, demonstrate the efficacy of therapeutically targeting this vulnerability.
- Xianbing Zhu
- , Zheng Fu
- & Sidong Huang
-
Article
| Open Access
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
In patients with locally advanced clear cell renal cell carcinoma (ccRCC), neoadjuvant therapy prior to curative nephrectomy has been shown to improve patient outcomes. Here, the authors report the safety and radiological efficacy of a phase II clinical trial investigating neoadjuvant sitravatinib (tyrosine kinase inhibitor) and nivolumab (PD-1 inhibitor) in locally advanced ccRCC.
- Jose A. Karam
- , Pavlos Msaouel
- & Christopher G. Wood
-
Article
| Open Access
TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway
The emergence of cisplatin resistance and side-effects are important factors in cancer treatment failure. Here, the authors identify autophagy-mediated EGFR hyperactivation by TRPV1 promotion as a mechanism of cisplatin resistance and demonstrate the efficacy of a TRPV1 inhibitor to sensitize lung cancer to cisplatin.
- Se Jin Oh
- , Ji Yeon Lim
- & Tae Woo Kim
-
Article
| Open Access
Nanoparticle-mediated TRPV1 channel blockade amplifies cancer thermo-immunotherapy via heat shock factor 1 modulation
TRPV1 has been associated with proliferation and survival of tumors, and can be activated by heat and other stimuli. Here, the authors block TRPV1 using photothermal nanoparticles encapsulating a TRPV1 antagonist in different cancer types, which can enhance thermo-immunotherapy in pancreatic cancer models.
- Ting Li
- , Shuhui Jiang
- & Huabing Chen
-
Article
| Open Access
DAXX drives de novo lipogenesis and contributes to tumorigenesis
Cancer cells have altered lipid metabolism. Here the authors show that DAXX promotes lipogenesis and tumorigenesis through interaction with SREBP1/2.
- Iqbal Mahmud
- , Guimei Tian
- & Daiqing Liao
-
Article
| Open Access
Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy
The clinical success of restoring P53 for cancer therapy has been limited due to toxicity. Here, the authors identify USP2 as an upstream regulator of VPRBP-mediated degradation of p53 and PD-L1 and demonstrate the efficacy of combining USP2 inhibitor and PD-L1/PD-1 immune checkpoint blockade in cancers.
- Jingjie Yi
- , Omid Tavana
- & Wei Gu
-
Article
| Open Access
TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks
The retention of 53BP1 at DNA double strand breaks (DSBs) is inhibitory to homologous recombination repair. Following ionising radiation, the authors demonstrate that TRABID-mediated deubiquitination of 53BP1 promotes its retention, sensitising prostate cancer to PARP inhibition.
- Jian Ma
- , Yingke Zhou
- & Lei Li
-
Article
| Open Access
IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis
Glioblastoma stem-like cells (GSCs) contribute to therapeutic resistance and recurrence of glioblastomas. Here the authors show that Insulin-like Growth Factor-Binding Protein 5 (IGFBP5) is a ligand for Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) promotes GSCs invasion.
- Weiwei Lin
- , Rui Niu
- & Jinlong Yin
-
Article
| Open Access
Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma
Genomic instability occurs infrequently in in diffuse large B cell lymphoma (DLBCL), suggesting a therapeutic vulnerability. Here, the authors identify a synergistic combination between the induction of polyploidy by a PLK4 inhibitor and a BCL-2 inhibitor in DLBCL.
- Ana Portelinha
- , Mariana da Silva Ferreira
- & Hans-Guido Wendel
-
Article
| Open Access
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
Hypomethylating agents, such as 5-Azacytidine (5-AZA), are standard of care for patients with myelodysplastic and myeloid malignancies, however response rates are limited and risk of relapses high. Here the authors show that inhibition of lysyl oxidases synergizes with 5-AZA to improve erythropoiesis and reduce disease burden in myelodysplastic neoplasms models.
- Qingyu Xu
- , Alexander Streuer
- & Daniel Nowak
-
Article
| Open Access
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
Treatment options in patients with recurrent endometrial carcinoma (EC) are limited and response rates to chemotherapy are poor. Here the authors report the results of a phase II trial of niraparib (PARP inhibitor) monotherapy or in combination with dostarlimab (anti-PD1) in recurrent EC.
- Ainhoa Madariaga
- , Swati Garg
- & Stephanie Lheureux
-
Article
| Open Access
RETRACTED ARTICLE: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer
Polymerase (POL) θ inhibitors display synthetic lethality in tumours with homologous recombination repair deficiency. Here, the authors demonstrate that POLθ inhibition with novobiocin activates the cGAS/STING pathway in BRCA-deficient cancers.
- Jeffrey Patterson-Fortin
- , Heta Jadhav
- & Geoffrey I. Shapiro
-
Article
| Open Access
ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors
CDKN2A loss and p53 mutations are rare in MYC-driven Group 3 medulloblastomas (MBs). Here the authors generated a transgenic mouse model of Group 3 MB by MYC overexpression and show that MYC suppresses ARF to drive tumorigenesis.
- Oliver J. Mainwaring
- , Holger Weishaupt
- & Fredrik J. Swartling
-
Article
| Open Access
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
In the phase III FLAURA study (NCT02296125), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib provided superior progression-free survival versus comparator EGFR-TKIs in patients with NSCLC. Here, by next-generation sequencing of circulating tumor DNA, the authors assess candidate mechanisms of acquired resistance to first-line osimertinib in patients from the FLAURA trial.
- Juliann Chmielecki
- , Jhanelle E. Gray
- & Suresh S. Ramalingam
Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers